Oncogenic Alterations of Metabolism Associated with Resistance to Chemotherapy

Overview

Journal Curr Mol Med

Publisher Bentham Science Publishers

Specialty Molecular Biology

Date 2023 Jun 23

PMID 37350008

Authors

Fahimeh Ghasemi

Tahereh Farkhondeh

Saeed Samarghandian

Alireza Ghasempour

Mehdi Shakibaie

Affiliations

Soon will be listed here.

Abstract

Metabolic reprogramming in cancer cells is a strategy to meet high proliferation rates, invasion, and metastasis. Also, several researchers indicated that the cellular metabolism changed during the resistance to chemotherapy. Since glycolytic enzymes play a prominent role in these alterations, the ability to reduce resistance to chemotherapy drugs is promising for cancer patients. Oscillating gene expression of these enzymes was involved in the proliferation, invasion, and metastasis of cancer cells. This review discussed the roles of some glycolytic enzymes associated with cancer progression and resistance to chemotherapy in the various cancer types.

Citing Articles

Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.

He X, Deng H, Liu W, Hu L, Tan X Curr Treat Options Oncol. 2024; 25(12):1615-1633.

PMID: 39633237 DOI: 10.1007/s11864-024-01279-0.

FOXA2 Activates RND1 to Regulate Arachidonic Acid Metabolism Pathway and Suppress Cisplatin Resistance in Lung Squamous Cell Carcinoma.

Zhou Y, Chen H, Yan J, Yao Q, Kong C, Peng Y Clin Respir J. 2024; 18(8):e13814.

PMID: 39129202 PMC: 11317498. DOI: 10.1111/crj.13814.

References

Martinez-Reyes I, Chandel N . Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020; 11(1):102. PMC: 6941980. DOI: 10.1038/s41467-019-13668-3. View

Bhattacharya B, Omar M, Soong R . The Warburg effect and drug resistance. Br J Pharmacol. 2016; 173(6):970-9. PMC: 4793921. DOI: 10.1111/bph.13422. View

Ganapathy-Kanniappan S, Geschwind J . Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013; 12:152. PMC: 4223729. DOI: 10.1186/1476-4598-12-152. View

Li C, Zhang G, Zhao L, Ma Z, Chen H . Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer. World J Surg Oncol. 2016; 14(1):15. PMC: 4721116. DOI: 10.1186/s12957-016-0769-9. View

Yang Y, Chuang H, Kuo W, Lin B, Chang Y . Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer. Int J Mol Sci. 2021; 22(19). PMC: 8508954. DOI: 10.3390/ijms221910612. View

Zhao H, Duan Q, Zhang Z, Li H, Wu H, Shen Q . Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. J Cell Mol Med. 2017; 21(9):2055-2067. PMC: 5571518. DOI: 10.1111/jcmm.13126. View

Ritterson Lew C, Tolan D . Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism. J Biol Chem. 2012; 287(51):42554-63. PMC: 3522257. DOI: 10.1074/jbc.M112.405969. View

Xintaropoulou C, Ward C, Wise A, Queckborner S, Turnbull A, Michie C . Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. BMC Cancer. 2018; 18(1):636. PMC: 5987622. DOI: 10.1186/s12885-018-4521-4. View

Mathupala S, Ko Y, Pedersen P . Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006; 25(34):4777-86. PMC: 3385868. DOI: 10.1038/sj.onc.1209603. View

10.

Li Z, Tang X, Luo Y, Chen B, Zhou C, Wu X . NK007 helps in mitigating paclitaxel resistance through p38MAPK activation and HK2 degradation in ovarian cancer. J Cell Physiol. 2019; 234(9):16178-16190. DOI: 10.1002/jcp.28278. View

11.

Lis P, Dylag M, Niedzwiecka K, Ko Y, Pedersen P, Goffeau A . The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate. Molecules. 2016; 21(12). PMC: 6273842. DOI: 10.3390/molecules21121730. View

12.

Wang H, Peng R, Chen X, Jia R, Huang C, Huang Y . Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer. Oncol Lett. 2018; 15(4):5553-5560. PMC: 5840691. DOI: 10.3892/ol.2018.8005. View

13.

Wang H, Wang L, Zhang Y, Wang J, Deng Y, Lin D . Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int. 2016; 16:9. PMC: 4755025. DOI: 10.1186/s12935-016-0280-y. View

14.

Yang H, Hou H, Zhao H, Yu T, Hu Y, Hu Y . HK2 Is a Crucial Downstream Regulator of miR-148a for the Maintenance of Sphere-Forming Property and Cisplatin Resistance in Cervical Cancer Cells. Front Oncol. 2021; 11:794015. PMC: 8631922. DOI: 10.3389/fonc.2021.794015. View

15.

Sato-Tadano A, Suzuki T, Amari M, Takagi K, Miki Y, Tamaki K . Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67. Cancer Sci. 2013; 104(10):1380-8. PMC: 7656546. DOI: 10.1111/cas.12238. View

16.

Pastorino J, Shulga N, Hoek J . Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2001; 277(9):7610-8. DOI: 10.1074/jbc.M109950200. View

17.

Gu J, Singh A, Xue K, Mavis C, Barth M, Yanamadala V . Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget. 2018; 9(3):4020-4033. PMC: 5790518. DOI: 10.18632/oncotarget.23425. View

18.

Zhang X, Zhang M, Cong Q, Zhang M, Zhang M, Lu Y . Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. Int J Biochem Cell Biol. 2017; 95:9-16. DOI: 10.1016/j.biocel.2017.12.010. View

19.

Botzer L, Maman S, Sagi-Assif O, Meshel T, Nevo I, Yron I . Hexokinase 2 is a determinant of neuroblastoma metastasis. Br J Cancer. 2016; 114(7):759-66. PMC: 4984856. DOI: 10.1038/bjc.2016.26. View

20.

Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H . Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy. 2008; 54(5):357-63. DOI: 10.1159/000153655. View